Recently, DSM-Firmenich has entered a strategic partnership with California-based biotechnology company Inscripta, aiming to co-develop a pioneering well-ageing skincare ingredient. Tapping into cutting-edge biotech innovation, the collaboration unites DSM-Firmenich’s deep expertise in skincare biotechnology with Inscripta’s advanced microbial strain engineering capabilities.
At the heart of the partnership is Inscripta’s proprietary GenoScaler platform, a next-generation genome engineering technology designed to enable robust, industrial-scale bio-manufacturing. The platform will be instrumental in creating high-performance bio-active ingredients that not only meet the growing consumer demand for effective skincare solutions but also align with rising expectations for sustainability.
“Partnering with DSM-Firmenich allows us to demonstrate the full potential of biotechnology in the beauty industry,” said Sri Kosaraju, President and CEO of Inscripta. “Our GenoScaler platform, combined with DSM-Firmenich’s vast experience in biotech, presents new opportunities for creating bio-actives that deliver both efficacy and sustainability.”
This collaboration reflects both companies’ shared commitment to innovation, environmental responsibility, and scalable manufacturing. By leveraging complementary strengths, the partnership aims to ensure supply chain security, consistent quality, and efficient use of natural resources.
Parand Salmassinia, President of Beauty & Care at DSM-Firmenich, emphasized the partnership’s potential: “By integrating Inscripta’s scientific knowledge with our biotechnology skincare expertise, we’re set to deliver next-generation well-ageing products that offer superior results while contributing to a more sustainable future. Our biotech leadership will ensure that we not only meet consumer expectations but exceed them.”
